Souvie Biodelivery is focused on developing a novel drug delivery platform technology that transports drug payload to and into the cells to which it is targeted, while having almost no effect on healthy tissues. Our exosome-based platform to support drug delivery, embodied in an innovative exosome-based therapy for the treatment of chronic auto-immune diseases and sepsis. Exosome-based therapeutics represent a novel class of biologics to treat human diseases.
We are improving drug delivery using novel biotechnology to avoid drug-induced side effects.
Souvie Biodelivery, LLC is drug delivery development company that employs nanotechnology to engineer, patent and market novel drug delivery platforms to drug delivery niche markets.